Intranasal sarbecovirus vaccine booster elicits cross-clade, durable and protective systemic and mucosal immunity
Nicholas You Zhi Cheang, Wee Chee YapiD, Kirsteen McInnes TullettiD, Xinlei QianiD, Peck Szee TaniD, Kiren PurushotormaniD, Wen‐Song TaniD, Shirley Yun Yan Mah, Paul A. MacAryiD, Chee Wah TaniD, Mireille Hanna LahoudiD, Sylvie AlonsoiD
Abstract
Short-lived, clade-specific immune responses with limited mucosal priming are limitations faced by current COVID-19 mRNA vaccines against sarbecoviruses. We have developed a nasal booster vaccine candidate that induced robust and sustained, cross-clade, systemic and mucosal protective immunity. Two recombinant Clec9A-specific monoclonal antibodies fused to the Receptor Binding Domain (RBD) from Omicron XBB.1.5 and SARS-CoV-1, respectively were generated. In Comirnaty mRNA-vaccinated mice, boosting with each individual Clec9A-RBD construct induced immune responses that either were limited in breadth or waned over time; while boosting with both constructs combined (Clec9AOMNI) elicited robust cross-clade neutralizing antibodies (nAb) and T cell responses that were significantly more sustained compared to Bivalent Comirnaty (BC) mRNA vaccine booster. The persistence of RBD-specific follicular helper CD4+ T cells, germinal centre B cells, and long-lived plasma cells that facilitated affinity maturation in Clec9AOMNI-boosted mice, correlated with the detection of triple cross-reactive B cells that bind to ancestral SARS-CoV-2 ancestral, SARS-CoV-2 XBB.1.5 and SARS-CoV-1 RBD. Remarkably, intranasal boosting with Clec9AOMNI generated robust and sustained mucosal immune responses in the upper and lower respiratory compartments, including RBD-specific IgA, cross-clade nAb and cellular immunity together with functional tissue-resident memory T cells, without compromising the systemic immune responses. Correspondingly, Clec9AOMNI booster conferred superior protection against Omicron BA.1 compared to BC booster when challenge was performed at six months post-boost. Hence, Clec9AOMNI is a promising nasal booster vaccine candidate that has the potential to mitigate pandemic threats from emerging sarbecoviruses. One Sentence SummaryNasal booster immunization with dendritic cell-targeting vaccine candidate in mRNA-vaccinated mice induced cross-clade, sustained, systemic and mucosal protective immunity.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses
T. Mao, B. Goldman-Israelow, … A. Iwasaki·bioRxiv·Jan 24, 2022
- Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates
M. Gagne, B. J. Flynn, … M Suthar·bioRxiv·Nov 6, 2023
- An Intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
P. A. van der Ley, A. Zariri, … C. P. Kruiswijk·Frontiers in ImmunologyPeer-reviewed·Dec 17, 2021
- Enhanced mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.
Gabriel Laghlali, Matthew J. Wiest, … Michael Schotsaert·Molecular TherapyPeer-reviewed·Oct 30, 2024
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization
D. Lapuente, J. Fuchs, … M. Tenbusch·bioRxiv·Aug 3, 2021
- Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
F. H. Damron, K. S. Lee, … R. K. Ernst·bioRxiv·Apr 25, 2023